Literature DB >> 32042497

Serum sickness following rituximab therapy in multiple sclerosis.

Trygve Holmøy1, Anna Fogdell-Hahn1, Anders Svenningsson1.   

Abstract

Entities:  

Year:  2019        PMID: 32042497      PMCID: PMC6927430          DOI: 10.1212/CPJ.0000000000000685

Source DB:  PubMed          Journal:  Neurol Clin Pract        ISSN: 2163-0402


× No keyword cloud information.
  7 in total

1.  Serum sickness and severe angioedema following rituximab therapy in RA.

Authors:  Ashok Kumar; Kundan Khamkar; Hemant Gopal
Journal:  Int J Rheum Dis       Date:  2011-08-31       Impact factor: 2.454

2.  Serum sickness following treatment with rituximab.

Authors:  Derrick J Todd; Simon M Helfgott
Journal:  J Rheumatol       Date:  2007-02       Impact factor: 4.666

Review 3.  Rituximab-induced serum sickness: A systematic review.

Authors:  Paras Karmacharya; Dilli Ram Poudel; Ranjan Pathak; Anthony A Donato; Sushil Ghimire; Smith Giri; Madan Raj Aryal; Clifton O Bingham
Journal:  Semin Arthritis Rheum       Date:  2015-06-26       Impact factor: 5.532

4.  A prospective clinical and immunologic analysis of patients with serum sickness.

Authors:  T J Lawley; L Bielory; P Gascon; K B Yancey; N S Young; M M Frank
Journal:  N Engl J Med       Date:  1984-11-29       Impact factor: 91.245

5.  B-cell depletion with rituximab in relapsing-remitting multiple sclerosis.

Authors:  Stephen L Hauser; Emmanuelle Waubant; Douglas L Arnold; Timothy Vollmer; Jack Antel; Robert J Fox; Amit Bar-Or; Michael Panzara; Neena Sarkar; Sunil Agarwal; Annette Langer-Gould; Craig H Smith
Journal:  N Engl J Med       Date:  2008-02-14       Impact factor: 91.245

6.  Rituximab versus fingolimod after natalizumab in multiple sclerosis patients.

Authors:  Peter Alping; Thomas Frisell; Lenka Novakova; Protik Islam-Jakobsson; Jonatan Salzer; Anna Björck; Markus Axelsson; Clas Malmeström; Katharina Fink; Jan Lycke; Anders Svenningsson; Fredrik Piehl
Journal:  Ann Neurol       Date:  2016-04-20       Impact factor: 10.422

7.  Rituximab in multiple sclerosis: Frequency and clinical relevance of anti-drug antibodies.

Authors:  Nicky Dunn; Alexander Juto; Malin Ryner; Ali Manouchehrinia; Luca Piccoli; Katharina Fink; Fredrik Piehl; Anna Fogdell-Hahn
Journal:  Mult Scler       Date:  2017-08-01       Impact factor: 6.312

  7 in total
  2 in total

1.  Drug Tolerant Anti-drug Antibody Assay for Infliximab Treatment in Clinical Practice Identifies Positive Cases Earlier.

Authors:  Nastya Kharlamova; Christina Hermanrud; Nicky Dunn; Malin Ryner; Karen Hambardzumyan; Nancy Vivar Pomiano; Per Marits; Inger Gjertsson; Saedis Saevarsdottir; Rille Pullerits; Anna Fogdell-Hahn
Journal:  Front Immunol       Date:  2020-07-21       Impact factor: 7.561

Review 2.  Recent progress in maintenance treatment of neuromyelitis optica spectrum disorder.

Authors:  Trygve Holmøy; Rune Alexander Høglund; Zsolt Illes; Kjell-Morten Myhr; Øivind Torkildsen
Journal:  J Neurol       Date:  2020-10-03       Impact factor: 6.682

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.